The editors of Scientific American have become the latest to call for an end to the decades-long ban on psychoactive drug research in the United States. In an article published in the February issue of the magazine, they write that legal restrictions on drugs like cannabis, MDMA, and LSD are hindering research that could have a significant impact on the treatment of mental illnesses and other health conditions. The authors of the article write that discoveries of new psychiatric medications have come to a virtual standstill and note that treatments for conditions like depression and schizophrenia have not advanced for decades. Innovations in the development of psychiatric medications would accelerate, they believe, if the legal status of psychoactive drugs were changed to make research easier to conduct. The authors recommend that, among other measures, psychoactive drugs like cannabis should be moved to a less strict Schedule II classification. Cannabis is currently classified as a Schedule I substance, the most restrictive category.